Skip to content
23 Apr 2020
Constipation is a very common, yet frustrating problem that can affect many of us at some point throughout our lives. Prevalence rates of constipation in the UK do vary, but worldwide 14% of the population have reported to suffer at some time1. Women are twice as likely to be affected as men and the elderly are more likely to suffer than younger individuals.
Subjectively, constipation can have different meanings for different people. Symptoms can be reported as any of the following:
For some people, managing their constipation is a daily undertaking. Common therapeutic options include dietary supplementation with fibre, such as psyllium husks or flax seeds, use of over-the-counter laxatives such as bisacodyl or senna-based stimulant laxatives and in severe cases, the use of prescription medication such as lactulose or lubiprostone.
Almost half of patients who suffer with chronic constipation are dissatisfied with conventional measures used to increase their stool frequency including laxatives and fibre supplements4. In the same population-based survey, 52% of those suffering with constipation reported that it significantly affected their quality of life. Therefore, many of those who suffer are looking for alternative options to help alleviate their symptoms and probiotics are becoming an increasingly popular choice.
Trillions of bacteria reside in the gut in what is known collectively as the gut microbiome. Find out more about your gut microbiome in our sister site, the Probiotics Learning Lab. These microbes live in an ideally harmonious equilibrium, with a balance between beneficial and pathogenic bacteria. However, certain lifestyle factors can disturb this balance leading to what is known as dysbiosis (glossary definition, in the Probiotics Learning Lab: dysbiosis). Dysbiosis has been often noted to be present in constipation5,6. Addressing this imbalance with a probiotic can help to restore normal bowel function and increase stool frequency.
Probiotics can play a key role in helping to relieve constipation, but it can be confusing trying to choose the correct and most effective one. Here we aim to demystify some of the confusion surrounding probiotics, and help you get the most out of your friendly bacteria. The majority of bacteria found in the large intestine are of the Bifidobacteria and Lactobacillus species, therefore it makes sense that probiotics with specific strains belonging to these species are generally regarded as the most beneficial in helping to alleviate constipation.
Although the exact mechanisms have not yet been fully elucidated 7, several suggested mechanisms by which probiotics can alleviate constipation include:
There are many possible triggers for constipation, and as a result there is no 'one size fits all' solution, fortunately though, there is good evidence to show that probiotics can be effective. It is important to be aware that each probiotic strain is different from the next. To meet your needs, it is always recommended that you select a strain that has been clinically trialled with a proven health benefit.
There are several strains of friendly bacteria that have been shown to be beneficial in helping to alleviate constipation in various clinical studies. The best probiotic supplements should contain strains which have been specifically researched for constipation including:
Bifidobacterium lactis BB-12® is an extensively researched probiotic strain shown to be effective for those with sluggish bowels. In one of the largest clinical trials assessing the effects of a probiotic strain, supplementation with B. lactis BB-12® was assessed in those suffering with decreased regularity11. A large multi-centre double-blind randomised placebo-controlled trial was conducted by Eskesen et al. involving 1000 subjects with low defecation frequency of 2 to 4 episodes per week. They were divided into 3 groups: one group were given 10 billion CFU of B. lactis BB-12® daily, the second group were given 1 billion CFU of B. lactis BB-12® daily and the third group were given a placebo, for 4 weeks. In the B. lactis BB-12® groups, there was a statistically significant increase in average defecation frequency compared with the placebo group from on average 3 episodes per week to 4 episodes per week at week 4.
B. lactis BB-12® has also been trialled successfully in specific groups of individuals more vulnerable to constipation such as the elderly and pregnant women. It has also been trialled in those with regular bowel movements and didn't increase defaecation rate - showing that it has a normalising effect.
You can find this strain in OptiBac 'Bifidobacteria & fibre'.
There have been several clinical studies to date assessing the effects of B. lactis HN019 in those with constipation.
In a gold standard trial (double blind, randomised controlled trial) by Ibarra et al., 228 adults diagnosed with constipation by their physician according to the ROME III guidelines, were divided into 3 groups 12. Each group were given either 10 billion of B. lactis HN019, 1 billion of B. lactis HN019 or a placebo daily for 28 days. Symptoms of constipation were monitored during and after the trial. In the intervention groups, there was a statistically significant increase in stool frequency in comparison with the placebo group. However, there was no alteration to colonic transit time in the probiotic groups.
In a triple-blind gold standard trial by Waller et al in which the effects of B. lactis HN019 on whole gut transit time constipated individuals was assessed 13. Participants chosen had functional gastrointestinal symptoms and a reduced stool frequency of 1 to 3 bowel movements per week. In total 88 participants completed the trial. They were divided into 3 groups: placebo group, low dose B. lactis HN019 group (1.8 billion CFU daily) and the high dose B. lactis HN019 group (17.2 billion CFU daily) for 14 days. Whole Gut Transit Time (WGTT) was assessed at day 0 and day 14 as each participant ingested radio-opaque markers followed by abdominal x-rays. Statistically significant reductions in WGTT were seen in the high dose (from 49 hours to 21 hours on average) and low dose (60 hours to 41 hours on average) B. lactis HN019 groups, which was not evident in the placebo group.
Of note, in a meta-analysis by Miller et al of 15 eligible randomised controlled trials assessing the effects of various probiotic strain supplementation on intestinal transit time, B. lactis HN019 was particularly noted to have medium to large treatment effects, suggesting that this strain is a viable option to consider to relieve constipation 14.
B. lactis DN-173 010 is another Bifidobacterium lactis strain shown to be effective at helping to relieve constipation in several clinical studies. In a double-blind parallel study in 70 healthy adults, drinking a daily combination of 375g of milk fermented with the specific Bifidobacterium lactis strain DN-173 010 (containing minimum 50 to 500 million CFU per dose) for 11 days reduced colon transit time by 20%. Interestingly, the effect was more pronounced in women 15. In another similar study, this time a gold standard trial, 12.5 billion CFU of B. lactis DN-173 010 was administered in yoghurt form to 34 individuals with IBS-constipation daily for 4 weeks. B. lactis DN-173 010 was demonstrated to significantly reduce colonic transit time from baseline (-12.2 hours) which was statistically significant comparted with placebo 16.
Lactobacillus rhamnosus GG® (or LGG® as it is more commonly known) is a very well-known and well-researched strain of probiotic bacteria with a range of known health benefits, some of which are suggested to include reducing constipation. Supplementation with LGG® has had some positive results in clinical trials in increasing stool frequency in constipated individuals, but was usually administered alongside another treatment such as fructo-oligosaccharides (a prebiotic fibre), which renders the true efficacy of LGG® alone, difficult to assess 17. Of note, a gold standard trial by Banaszkiewicz et al. failed to demonstrate significant benefits in the alleviation of constipation using LGG® alone. Ideally, further clinical studies would be performed to accurately assess its efficacy 18.
In addition to probiotics, it is worth mentioning that prebiotics may also be helpful in relieving constipation. Prebiotics act as a food source for the probiotics and help to stimulate the activity of beneficial colonic bacteria. They are thought to have a small laxative effect, but with no risk of dependency. A combination of the probiotic Bifidobacterium lactis BB-12® and prebiotic fibres are widely recognised as an effective remedy to help alleviate constipation and maintain normal bowel function.
There are also certain foods you can include in your diet which may help to boost levels of beneficial bacteria and support digestive health. Probiotic foods such as natural live yogurt and fermented foods (e.g sauerkraut and kimchi) are rich in Lactobacillus bacteria.
This article was written by Dr Aisling Dwyer MB BCh BAO (Medicine, Surgery and Obstetrics), MSc (Personalised Nutrition) in collaboration with Kerry Beeson BSc (Nut. Med.) Nutritional Therapist and was last updated on 18th September 2020.
1. Suares NC, Ford AC. Prevalence of, and risk factors for, chronic idiopathic constipation in the community: Systematic review and meta-analysis. Am J Gastroenterol. 2011;106(9):1582-1591. doi:10.1038/ajg.2011.164
2. Simren M, Palsson OS, Whitehead WE. Update on Rome IV Criteria for Colorectal Disorders: Implications for Clinical Practice. Curr Gastroenterol Rep. 2017;19(4). doi:10.1007/s11894-017-0554-0
3. Rao SSC, Rattanakovit K, Patcharatrakul T. Diagnosis and management of chronic constipation in adults. Nat Rev Gastroenterol Hepatol. 2016;13(5):295-305. doi:10.1038/nrgastro.2016.53
4. Johanson JF, Kralstein J. Chronic constipation: A survey of the patient perspective. Aliment Pharmacol Ther. 2007;25(5):599-608. doi:10.1111/j.1365-2036.2006.03238.x
5. Chassard C, Dapoigny M, Scott KP, et al. Functional dysbiosis within the gut microbiota of patients with constipated-irritable bowel syndrome. Aliment Pharmacol Ther. 2012;35(7):828-838. doi:10.1111/j.1365-2036.2012.05007.x
6. Kim S-E, Choi SC, Park KS, et al. Change of Fecal Flora and Effectiveness of the Short-term VSL#3 Probiotic Treatment in Patients With Functional Constipation. J Neurogastroenterol Motil. 2015;21(1):111-120. doi:10.5056/jnm14048
7. Dimidi E, Mark Scott S, Whelan K. Probiotics and constipation: Mechanisms of action, evidence for effectiveness and utilisation by patients and healthcare professionals. Proc Nutr Soc. 2020;79(1):147-157. doi:10.1017/S0029665119000934
8. LeBlanc JG, Chain F, Martín R, Bermúdez-Humarán LG, Courau S, Langella P. Beneficial effects on host energy metabolism of short-chain fatty acids and vitamins produced by commensal and probiotic bacteria. Microb Cell Fact. 2017;16(1). doi:10.1186/s12934-017-0691-z
9. Salminen S, Salminen E. Lactulose, lactic acid bacteria, intestinal microecology and mucosal protection. Scand J Gastroenterol Suppl. 1997;32(222):45-48. doi:10.1080/00365521.1997.11720717
10. Ge X, Zhao W, Ding C, et al. Potential role of fecal microbiota from patients with slow transit constipation in the regulation of gastrointestinal motility. Sci Rep. 2017;7(1):441. doi:10.1038/s41598-017-00612-y
11. Eskesen D, Jespersen L, Michelsen B, Whorwell PJ, Müller-Lissner S, Morberg CM. Effect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: A randomised, double-blind, placebo-controlled, parallel-group trial. Br J Nutr. 2015;114(10):1638-1646. doi:10.1017/S0007114515003347
12. Ibarra A, Latreille-Barbier M, Donazzolo Y, Pelletier X, Ouwehand AC. Effects of 28-day Bifidobacterium animalis subsp. lactis HN019 supplementation on colonic transit time and gastrointestinal symptoms in adults with functional constipation: A double-blind, randomized, placebo-controlled, and dose-ranging trial. Gut Microbes. 2018;9(3):236-251. doi:10.1080/19490976.2017.1412908
13. Waller PA, Gopal PK, Leyer GJ, et al. Dose-response effect of Bifidobacterium lactis HN019 on whole gut transit time and functional gastrointestinal symptoms in adults. Scand J Gastroenterol. 2011;46(9):1057-1064. doi:10.3109/00365521.2011.584895
14. Miller LE, Zimmermann AK, Ouwehand AC. Contemporary meta-analysis of short-term probiotic consumption on gastrointestinal transit. World J Gastroenterol. 2016;22(21):5122-5131. doi:10.3748/wjg.v22.i21.5122
15. Marteau P, Cuillerier E, Meance S, et al. Bifidobacterium animalis strain DN-173 010 shortens the colonic transit time in healthy women: a double-blind, randomized, controlled study. Aliment Pharmacol Ther. 2002;16(3):587-593. doi:10.1046/j.1365-2036.2002.01188.x
16. Agrawal A, Houghton LA, Morris J, et al. The effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2009;29(1):104-114. doi:10.1111/j.1365-2036.2008.03853.x
17. Granata M, Brandi G, Borsari A, Gasbarri R, Di Gioia D. Synbiotic yogurt consumption by healthy adults and the elderly: The fate of bifidobacteria and LGG probiotic strain. Int J Food Sci Nutr. 2013;64(2):162-168. doi:10.3109/09637486.2012.718742
18. Banaszkiewicz A, Szajewska H. Ineffectiveness of Lactobacillus GG as an adjunct to lactulose for the treatment of constipation in children: A double-blind, placebo-controlled randomized trial. J Pediatr. 2005;146(3):364-369. doi:10.1016/j.jpeds.2004.10.022
This article was written by Dr Aisling Dwyer MB BCh BAO (Medicine, Surgery and Obstetrics), MSc (Personalised Nutrition) in collaboration with Kerry Beeson BSc (Nut. Med.) Nutritional Therapist and was last updated on 24th April 2020.